25 related articles for article (PubMed ID: 15850522)
1. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
Zhu M; Xu B; Yao GB
Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
[TBL] [Abstract][Full Text] [Related]
2. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
[TBL] [Abstract][Full Text] [Related]
3. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.
Chien RN; Liaw YF; Atkins M
Hepatology; 1999 Sep; 30(3):770-4. PubMed ID: 10462384
[TBL] [Abstract][Full Text] [Related]
4. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.
Fung J; Lai CL; Tanaka Y; Mizokami M; Yuen J; Wong DK; Yuen MF
Am J Gastroenterol; 2009 Aug; 104(8):1940-6; quiz 1947. PubMed ID: 19455108
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B.
Shin JW; Park NH; Park JH; Park JH; Jeong ID; Bang SJ; Joo KR; Kim DH
J Viral Hepat; 2005 Jul; 12(4):393-7. PubMed ID: 15985010
[TBL] [Abstract][Full Text] [Related]
6. [A long-term observation and follow-up for patients with HBeAg/Anti-HBe seroconversion after lamivudine treatment].
Wu JL; Li SG; Wen FY; Yang XY; Zhou HJ
Zhonghua Gan Zang Bing Za Zhi; 2005 Apr; 13(4):297-9. PubMed ID: 15850522
[TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic hepatitis B.
Lagget M; Rizzetto M
Curr Pharm Des; 2002; 8(11):953-8. PubMed ID: 11945141
[TBL] [Abstract][Full Text] [Related]
8. Lamivudine for the treatment of chronic hepatitis B.
Dixon JS; Boehme RE
Acta Gastroenterol Belg; 2000; 63(4):348-56. PubMed ID: 11233517
[TBL] [Abstract][Full Text] [Related]
9. The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B.
Dienstag JL
J Hepatol; 2005 Feb; 42(2):158-62. PubMed ID: 15664237
[No Abstract] [Full Text] [Related]
10. Treatment of chronic hepatitis B: from research to clinical practice via the consensus conferences.
Brunetto MR; Bonino F
Curr Pharm Des; 2004; 10(17):2063-75. PubMed ID: 15279545
[TBL] [Abstract][Full Text] [Related]
11. Time-dependent events in natural history of occult hepatitis B virus infection: the importance of population-based long-term follow-up study with repeated measurements.
Chen CJ
J Hepatol; 2005 Apr; 42(4):438-40. PubMed ID: 15763321
[No Abstract] [Full Text] [Related]
12. [HBe antigen and HBe antibody].
Arase Y; Kumada H
Nihon Rinsho; 1995 Oct; 53 Suppl(Pt 2):247-52. PubMed ID: 12442393
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
